Clinical Results
Over 18 months Homotaurine reduces the loss of hippocampal volume by 68% compared to placebo.
Homotaurine showed a 33% better result in cognitive performance tests (ADAS-cog) vs. placebo at 12 months.
A major groundbreaking study performed in Canada and the United States using brain scans (magnetic resonance imaging (MRI)), showed that homotaurine, the active ingredient in VIVIMIND™, can protect the hippocampus, the portion of the brain associated with a person’s ability to learn and remember, by showing that homotaurine reduces the loss of volume by 68 per cent when compared to placebo (like a sugar pill)(2).
Individuals taking VIVIMIND™ also performed better on tests of memory and thinking compared with individuals taking placebo. VIVIMIND™ was found to improve cognitive performance by 33% versus the placebo (like a sugar pill)(2).
- North American and European phase 3 clinical trials – data on file BELLUS Health.
- Post-hoc analysis of a 78-week Phase III North American study in 1052 mild-to-moderate Alzheimer’s disease patients 50 and older.
